New drug PG-033 enters first human safety tests

This early-stage study tests the safety of a new drug called PG-033 in 52 healthy adults aged 18 to 45. Participants receive either a single dose of PG-033 or a placebo, and researchers monitor side effects and how the drug moves through the body. The study also checks if a high-fat meal changes drug absorption. No treatment benefit is expected; the goal is to gather safety information for future research.